Information Provided By:
Fly News Breaks for October 27, 2015
MDVN
Oct 27, 2015 | 07:39 EDT
Jefferies analyst Biren Amin lowered his price target for Medivation to $50 after his survey of 60 physicians indicated moderating growth for Xtandi . The analyst now believes consensus sales estimates in 2016-2019 for the drug look high. Xtandi is likely near peak market share in the pre/post chemo setting, Amin tells investors in a research note. He keeps a Hold rating on Medivation.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.